XL228
货号：
21506-50mg 基本售价：
6622.0 元 规格：
50 mg
产品信息
概述| 货号 | 21506-50mg |
| 描述 | XL228 potently inhibits the tyrosine kinases IGF1R (IC50 = 1.6 nM) and FGFR1-3 (IC50< 100 nM), which promote tumor growth, and SRC (IC50 = 6.1 nM), which mediates metastasis.1,2 It also inhibits the non-receptor tyrosine kinases BCR-ABL (IC50 = 1.4 nM) and Aurora A (IC50 = 3.1 nM), associated with chronic myelogenous leukemia. XL228 showed promising preliminary results in a Phase 1 clinical trial for patients with chronic myelogenous leukemia or Philadelphia-chromosome-positive acute lymphocytic leukemia but the trial was terminated early.2 |
性能| 供应商 | Cayman |
| 应用文献 |
1.Clary, D.O.,Ollmann, M.M.,Detmer, S.A., et al. Abstract C192: Characterization of the target profile of XL228, a multi‐targeted protein kinase inhibitor in phase 1 clinical development. Mol. Cancer. Ther. 8(12 Suppl), C1952 (2009).
2.Cortes, J.,Paquette, R.,Talpaz, M., et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF- 1R/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood 112(11), 3232 (2008).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 437.5 |
| 分子式 | C22H31N9O |
| CAS号 | 898280-07-4 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
